Outback senators

On 13-Nov-2006 Amgen (NASDAQ: AMGN) announced that data from an ongoing open-categorize, multinational, phase 4 annexe study showed that patients with ankylosing spondylitis (AS) who received treatment with Enbrel (etanercept) experienced unchanged recuperation in signs and symptoms, spinal mobility and navy surgeon function over 148 to 160 weeks of therapy. These results are predictable with an ENBREL phase 3 clinical trial at 24 weeks. The 160-week results desire be presented at the American College of Rheumatology (ACR) Methodical Meeting in Washington, D.C.

“These matter demonstrate that ENBREL can get ready for profitable fancy-term repair in AS symptoms such as total back pain and spinal mobility,” said Joachim Sieper, M.D., professor of rheumatology, Charite University in Berlin, Germany. “Because AS is a chronic inflammatory disease that requires endless management, it is important to put on the market patients a treatment choice that is basic, has an established safety profile, and can be old over the long-term.”

Evidence presented at ACR showed that 59 patients who received open-label ENBREL treatment for up to 160 weeks experienced sustained clinical improvements. Overall, 78 percent of patients (n=46) continuing treatment with ENBREL achieved a 20 percent improvement in the Assessment on Ankylosing Spondylitis Rejoinder Criteria (ASAS 20) after 160 weeks of treatment. ASAS is a composite measure of improvement in AS symptoms that include amount to back pain, philosophical assessment of disease occupation, inflammation and carnal responsibility. Thirty-one percent of patients (n= 18) achieved affinity to exculpation at week 160. Partial remission, as defined by ASAS, is a lesser disease activity level (score < 20 units visible of 100 in each of the four ASAS criteria).

Additional ENBREL data presented at ACR from this phase 4 extension study indicate that improvement in spinal mobility was also continuous past 148 to 160 weeks of treatment with ENBREL.

Impotencia masculina

Patients with ankylosing spondylitis get reported that their health circumstances has negatively impacted their genius to perform daily activities including exercising, rising from a seated position and climbing stairs without aid. Comprehensive, patients treated with ENBREL achieved a 46 percent improvement in physical function, as measured by the Bath Ankylosing Spondylitis Effective Index (BASFI), and these results were level through 160 weeks. The BASFI is a 10-question, patient self-assessment catalyst consisting of 8 particular questions regarding physical function in AS and 2 questions reflecting the patient’s capacity to cope with mediocre life. Each entertain is answered on a 10 cm horizontal visual analog ratio, the no matter what of which gives the BASFI avenge (0-10).

ENBREL was generally well tolerated all over 148 to 160 weeks of therapy.

This examine was designed to assess the shelter and long-term efficacy of ENBREL in patients with AS, using clinical measures to assess disease undertaking, physical function, improvement in AS symptoms, and ceaseless surveillance to assess the degree of adverse events. The study is a 96-week susceptible-label, multinational, phase 4 extension study in 59 patients with AS who completed each of two earlier trials, a 12-week randomized, double-weak-minded, placebo-controlled library and a 96-week open-label mug up. The data presented at ACR is from the in the first place 52-weeks of an ongoing 96-week amplification mull over (total ENBREL treatment 148 - 160 weeks).

Enbrel received FDA affirmation to treat the signs and symptoms of effectual AS in 2003 following a randomized, counterpart-blind, placebo-controlled phase 3 study in 277 patients with acting ankylosing spondylitis. Treatment with ENBREL (n=138) resulted in significant clinical improvements through 24 weeks, compared to placebo (n=139). At 12 weeks, the ASAS 20 response was achieved by 60 percent of patients receiving ENBREL, compared to 27 percent of patients receiving placebo (p

Do you suffer from cold sores? If so, then you certainly neediness a medicine that can down their duration for unshakable. Nicely, Valtrex unheated sore medication help in this relate to? Here is a patch to let slip some answers.

As a cold sore remedy, Valtrex by Glaxo Smith Kline could be one of the best medicines available. Valtrex is the brand name for valacyclovir hydrochloride. It comes in pill form for treating shingles, cold sores or herpes simplex, as well as varicella and herpes zoster.

cialis

While Valtrex is one of the best as a cold sore remedy, is not cheap. A 500-mg pill costs about $ 6.00 each, while a 1000 mg pill will run $ 10.00 each. Taking four 1,000 mg tablets costs $ 40, but if you are suffering from a cold sore, I think it is money well spent.

I have a friend who suffers from a number of attacks with cold sores throughout the year. He has tried every remedy cold sore, cold sore medication, and any other home remedy for cold sores. Nothing has worked for him as Valtrex.

That after Taking Valtrex and the instructions say to do, at the first sign of a tingling sensation. He took two tablets 1000 mg twice daily for one day. The cold sore was not reaching out. never broke the surface. This was surprising.

If you suffer from cold sores, then you know that when you leave you’re looking at 10-14 days of an ugly, painful cold sore. If you are taking Valtrex this will not happen. Especially compared with the cold sore remedy, no doubt about what is best.

The key for any cold sore medication to work is catching the sore before it breaks through the surface of your skin. Once it breaks there is no cold sore remedy to remove in a day or two, including Valtrex. But if you take Valtrex before this happens, then flat to remove immediately.

For anyone who has cold sores and has been looking for a medicine that works, talk to your doctor or healthcare provider about Valtrex. It may be cold sore remedy you’re looking for.

All rights reserved throughout the world. Reprint Rights: You may reproduce this article, provided they leave all links active and do not edit the article in any way.

Chugai Pharmaceutical Co., Ltd. announced that on July 15 the company will available a permanent exhibit entitled “Dr. Kitanomaru’s Bio Pharmaceutical Laboratory” at the System Museum (Chiyoda-ku, Tokyo). The aim of the brandish is to abet greater regard in system amidst children through an awareness of medicine, biotechnology, and the indicated illness of cancer, through a series of video presentations. It is hoped that the majority of children who view the exhibit want be convinced that information is exciting.

The Chugai expose inclination be the essential sponsored by a pharmaceutical gathering at the Science Museum, which was established to promote a greater armistice of body of laws and industrial technology.

Impotencia

“Dr. Kitanomaru’s Bio Pharmaceutical Laboratory” drive take the form of a single human cubicle occupying the entire 10-meter wide, 2.5-meter deep-rooted booth, complete with all the diversified organelles that make up a cell, such as the nucleus, endoplasmic reticulum, and mitochondria, presented to enable the viewer to allow at a gleam what organelles go together to make up the cells that regimen the benefactor league. Visitors wish also be able to learn in detail with medicine, biotechnology, and specifically the disorder of cancer, while watching videos inside the kiosk of living cells and other parts of the body, as seen through a microscope.

The focusing is to encourage children to befit familiar with concepts of biotechnology, subsistence, and the cell by associating these concepts with their own bodies, outstanding to a greater reconciliation of, and deeper avail in, these topics.

To look at the hole of the permanent exhibit, on Sunday, July 23 Chugai will hotelman a lecture meeting entitled “Fall in! Young man researchers of Biotechnology and Medicine” at the museum’s Science Hired hall. The meeting will attribute Professor Hiroshi Suzuki of the University of Tokyo’s Permission of Medicament and Professor Tsutomu Tsuji of Hoshi University, who will give accommodating-to-conform to talks interspersed with video on the topics “The Science of Recent Medicines” and “Using Biotechnology to Comprehend Medicines.”
As a supreme company in the field of biopharmaceuticals, Chugai is an active supporter of this country’s science and technology policy and is eager to provide to fostering chic gift for the unborn of next-generation science and technology, as well as to stimulate greater awareness of science and technology among the run-of-the-mill public.

We strongly hope that “Dr. Kitanomaru’s Bio Pharmaceutical Laboratory” durable show force encourage flat more children to take an interest in science, both as a subject in school and in a more unspecialized sense.

http://www.chugai-pharm.co.jp

How many Americans have psoriasis? Is it “as myriad as 7.5 million,” “5 million” or some other number? Both of those
figures have appeared recently in media reports on psoriasis, and millions of dollars in medical research funding may ride on
the answer. To find the answer, Psoriasis Cure Now, a sufferer advocacy grouping, today launched an effort to get the Centers
for Disease Control and Prevention (CDC) to comport a definitive count of Americans with psoriasis.

“No one seems to be able to allow how many Americans have psoriasis, and this mortification may be hurting us in Congress,” said
Michael Paranzino, president of Psoriasis Cure Now. “One of the most frequent questions I get asked on Capitol Hill is how
diverse Americans have the virus, and the number of people impacted by a disease apparently affects its research funding. Assumption
that psoriasis check out funding is down 8% over the form decade as medical research funding for other diseases is up 99%,
it’s constantly to get this definitely answered accurately.”

The National Institutes of Health’s (NIH) National Institute of Arthritis and Musculoskeletal and Hull Diseases says that
there are “between 5.8 and 7.5 million” Americans with psoriasis, but some reports pick up to imply there are 4.5 million
or 5 million Americans with the infirmity. Put asunder give up of the confusion comes from studies that exclude all children, or exclude
anyone with the disease who does not deliver a physician’s diagnosis to destroy it up, still notwithstanding that a group of dermatologists and
elemental heedfulness physicians recently surveyed by Datamonitor estimated as many as half of psoriasis patients may be undiagnosed.

“No one should be using figures that exclude my daughter Jessica or the hundreds of thousands of other children who have
psoriasis,” said Marielle Gagarin of Grand Rapids, Michigan, whose nine year-old daughter has had severe psoriasis for three
years. “We desperate straits the government to adjudge years and suited for all how many Americans of all ages have psoriasis and to commit the
research funding to descry a mend for the sake of this debilitating and currently incurable disease.”

Psoriasis Cure Now has launched an e-suit enabling Americans to urge the CDC to conduct an exact count of all
psoriasis patients, including children, as well as adults who have the ailment but have not been seen by a doctor for it. It
also asks CDC to determine how numberless Americans have psoriatic arthritis, another poorly-understood virus. CDC is currently
preparing to release materials on psoriasis, but its study reportedly will exclude everyone under age 20 and over life-span 59, connotation
millions of psoriasis patients will be missed. The e-plea letter to CDC is available here: http://capwiz.com/psorcurenow/home .

Psoriasis is an incurable, recurring disease of the immune system that can first strike at any duration, causing tiring, throbbing skin
lesions that can instant, bleed and itch. Many people with psoriasis also have psoriatic arthritis, a long-standing, revolutionary and
debilitating inflammatory disease that frequently causes joint pain, stiffness and swelling, as well as bone damage.

viagra generico en españa

Michael Paranzino
Psoriasis Correct Once in a blue moon
202-253-4863
michael@psorcurenow.org
http://www.psorcurenow.org

Fruits and vegetables - tasty and a vital business of daily nutrition. But researchers worldwide persevere in to seek better ways to use the healthful properties of these foods. Many of these scientists longing meet in Houston Oct. 9-13 to share the latest findings.

FAV Salubrity 2007 — Fruits And Vegetables, that is — liking convene at the Omni Hotel Houston, Four Riverway, for the second international symposium on how create affects human health, according to Dr. Bhimu Patil, director of the Texas A&M University Vegetable and Fruit Improvement Center and discussion chair.

Patil said sessions at one’s desire include the exercise of fruits and vegetables to tone down the risks of obesity, cancer and diseases of the nerve, intellect and skin. Presenters also disposition talk hither how to maintain the most healthful knock down of bioactive compounds in the pre- and send-pick stages of fruit and vegetable assembly, as well as the interaction of certain medicines with grapefruit and other foods.

A general session will-power pinpoint on strength-based marketing of fruits and vegetables. Additionally, divers epidemic food-related organizations devise have a round table bull session about future funding challenges to meet world nutrition needs.

—————————-
Article adapted by Medical News Today from pattern press deliver.
—————————-

Participants can register until Aug. 16 as far as something $595, which includes meals, a meal and conference materials. Into more poop, see http://favhealth2007.tamu.edu/.

Viagra

Source: Kathleen Phillips

Texas A&M University - Agricultural Communications

Even though compelling benumb cocktails have improved the outlook for many patients with HIV, disorder progression, including the time from AIDS onslaught to passing, varies substantially from patient to patient.

Now, a study led by the University of North Carolina at Chapel Hill School of Medicine provides new evidence that psychological factors play a role in disease progression.

The study is the first-known in the era of highly active antiretroviral therapy (HAART) for HIV to show that traumatic life events, such as physical or sexual abuse, are associated with faster mortality, both from AIDS-related and all causes.

“Trauma and depression are common among people with HIV, and trauma and depression seem to have an effect on disease progression and mortality in HIV. Given that, it is critical that clinicians treating people infected with HIV recognize depression and trauma as risk factors for poor health outcomes, and thus screen and refer patients for psychological and psychiatric treatment when these problems are present,� said Jane Leserman, Ph.D., professor of psychiatry and medicine and lead author of the study.

“Some combination of cognitive behavioral therapy and medication might be very beneficial for patients experiencing severe or multiple types of trauma,� Leserman said.

comprar viagra espana

The study is published in the Nov. 1, 2007 edition of the American Journal of Psychiatry.

The researchers interviewed a group of 490 HIV infected patients in the rural southeast. Those who reported a greater number of categories of traumatic life events had faster death from all causes and from AIDS. More than half of the patients in the study experienced three or more lifetime traumas, and half had experienced physical or sexual abuse.

Unlike depression, the effects of which have been more widely studied in the era of HAART, with trauma, it’s possible to establish a time ordering of events.

“In our study, these traumatic events occurred in most cases many years before the progression of the patients’ HIV. So it’s a more compelling argument for a causal effect of trauma,â€? Leserman said. “Trauma, most of it occurring two or more years before the study, seemed to continue to have a major impact on these patients.â€?

Leserman hopes to study whether treating HIV patients for trauma results in better health outcomes. “We need further study of trauma treatment in this population to find out if that attenuates some of the negative effects,� she said.

http://www.unc.edu/

Where and why is Reductil Sibutramine used?

Reductil Sibutramine is proven to reduce appetite and enhance satiety. The first of a new generation of weight loss drugs, Reductil Sibutramine offers a long-term weight control option when used as an add-on to diet and exercise. The EU license for Sibutramine permits continuous treatment for periods of up to 1 year; although the US FDA has already extended its clearance to 2 years.

Sibutramine is indicated for use in patients:

With a BMI >30 kg/m2 and in overweight patients with a BMI >27 kg/m2 with additional obesity-related risk factors like type 2 diabetes or dyslipidaemia Who have had difficulty in losing weight with weight-reducing diet and exercise alone Who have lost at least 2kg weight in four weeks and 5% of initial weight within three months of starting Sibutramine; if not, it should be stopped Who are between the ages of 18 and 65 years Who continue to lose weight with Sibutramine usage; these patients’ can continue to take Sibutramine for a maximum of one year

How effective is Sibutramine?

Studies have revealed that by and large, Reductil Sibutramine when combined with a weight-reducing diet and exercise can result in increased weight loss. In fact, Sibutramine results have been so promising with people losing up to or more than 7% of total body weight within 6-12 months. Without Sibutramine, diet and exercise has proven less effective.

Efficacy of Sibutramine also depends on one’s continued efforts to persist with the diet and exercise regimen alongside Sibutramine. Sibutramine in itself does not work on body fat but on the appetite controlling neurotransmitters in the brain; maintaining a healthy weight-reducing diet and exercise regimen is what helps Sibutramine work for us in a positive manner.

Is it safe to use Sibutramine for an extended period of time?

Up until the approval of Reductil Sibutramine in 1997, most weight loss medications were prescribed for no longer than three months. Sibutramine is approved for up to one year, but, at a doctor’s discretion, it may be prescribed for longer periods but never more than two years. Long-term use of Sibutramine may result in an increase in blood pressure and thus require monitoring by a medical professional.

However, Sibutramine plays an essential role in medical treatment, more so now that obesity has now been accepted as a metabolic disease. Obesity is now no longer thought of as a failure of desire or willpower. In fact, most clinicians opine that obesity is often easier to manage with a sensible use of weight loss medications.

Impotencia

Can Sibutramine provide a permanent solution for obesity?

No medication provides a permanent solution for obesity – whether it is prescription medication, over-the-counter drugs or herbal medications. All these medications, including Sibutramine can only do so much, and no more. Reductil Sibutramine can set your weight loss programme in motion but it is up you – the individual – to continue your fight against the bulge. Once Sibutramine has run its course, because it can no longer be taken after a two-year period, your efforts at eating and exercising right will help you win and sustain your battle against obesity.

How can I start treatment with Sibutramine?

Any weight loss treatment drugs should be used only in combination with lifestyle modifications which will help you recognize and change your behavior that led to the weight gain. Drug therapy when combined with comprehensive counseling program can also promote increased weight loss and adequate weight management. Counseling can help establish realistic goals as even modest weight loss helps.

In the past, all we had to worry about was our knack, or inability, to resist fattening foods. According to late-model investigating, diverse cases of obesity may be the result of an contagious bug - more specifically, the human adenovirus Ad-37.

According to Dr L Whigham and team, Dept of Nutritional Sciences, Wisconsin University, tubbiness is a chronic and complex disease. He says that there are lots of factors contributing to the broad epidemic. He adds that it is precise conceivable that the obesity explosion is partially suitable to an infectious malady.

You can read back this study in the American Journal of Physiology, Regulatory Integrative and Comparative Physiology.

Dr Whigham says the human adenovirus Ad-37 makes chickens pudgy. Earlier studies give birth to indicated that other viruses, which are found in humans, can also trigger plumpness. Whighan says his team bring into the world identified three viruses that make chickens, and most likely humans, fat. He says further examine is needed to see how many of the other 50 or so adenoviruses may include alike resemble effects.

The enquire team says the validation is strong that viruses tip off a exaggerate humans and animals fat - they raise the amount of fat we conduct in our paunchiness cells.

Comprar viagra espana

The pointing of the duo, after they be dressed concluded their studies and identified which viruses make us fat, is to develop an anti-obesity vaccine that targets these viruses.

Dr Whigham said there are people who are not pudginess but carry the virus. He stressed that good diet and exercise relieve plays a crucial rele in regulating our weight and orderly health. He says he does not know how diet and exercise interact with the virus.

Many participate in written to Medical Intelligence Today on this text. The ordinary thread among the e-mails is that diet and bones bustle play the principal roles on how much we weigh. We all lead alarmingly sedentary lives and we eat too much processed junk food - and too much commons.

One person emailed in with: ‘These chickens in the study that got five-by-five because they had the virus - were they sedentary? What would prove if you split the chickens up into two groups? One organization with the virus, but doing lots of exercise and eating good rations in the right quantity, and the other club without the virus, sedentary, with loads of fattening food. I bet the second group would be fatter. Perhaps the virus plays a delicate position - but I am inescapable diet and exercise are the factors that really matter.’

Written by: Christian Nordqvist
Editor: Medical Despatch Today

Copyright: Medical News Today

Not to be reproduced without leave of Medical Expose Today

Scientists at Prince Henry’s Institute, Melbourne, and the University of California, Los Angeles, have discovered that SRY, the male protein that forms the testes is also produced in the brain region affected in Parkinson’s complaint. This discovery may resolve why men are more indubitably than women to develop this degenerative disorder.

“Our research has shown that a gene only present in males contributes to the control of physical movement, a fundamental brain function,” said Associate Professor Vincent Harley, Head of the Human Molecular Genetics Group at Prince Henry’s Institute.

Parkinson’s disease is a chronic movement disorder that affects an estimated 40,000 Australians. Men are 1.5 times more likely to develop the disease than women.

SRY, the protein that determines male gender, was discovered by British scientists in 1990. Dr Harley joined the team and was the first to show functions of the SRY protein in males. SRY is passed from father to son on the Y chromosome and is not present in females.

Co-investigators Dr Eric Vilain of UCLA and Dr Harley have now traced the SRY protein to a region of the brain called the substantia nigra, which deteriorates in Parkinson’s disease.

Parkinson’s disease develops when cells in the substantia nigra begin to malfunction and die, producing less dopamine. Dopamine, a chemical messenger, communicates with the brain to control movement and co-ordination. People with Parkinson’s disease become unable to initiate or control their physical movements, eventually leading to paralysis.

The Prince Henry’s Institute team, led by Dr Harley, developed sensitive new tools to detect SRY protein in the brain. UCLA scientists, led by Dr Vilain, lowered the level of SRY in the substantia nigra in animal models and detected a corresponding drop in tyrosine hydroxylase, which plays a key role in the brain’s production of dopamine. The consequent low dopamine levels resulted in Parkinson’s-like movement problems.

Tadalafil

Drs Vilain and Harley believe that the variations in genes that control SRY or in the SRY gene itself may be linked to the onset of Parkinson’s disease. Men with low levels of SRY may be at greater risk of developing the disease.

“We were surprised to find a function for SRY outside the testes,” said Dr Harley.

Scientists at Prince Henry’s Institute are collaborating with Associate Professor Catriona McLean, Director of the National Neural Tissue Resource Centre at the Alfred Hospital, Melbourne, to investigate SRY levels in the brains of males with Parkinson’s disease.

Drs Harley and Vilain suspect that the normal role of SRY in the male brain could be to provide a protective effect against Parkinson’s disease.

“The SRY gene may also explain the sex differences in other dopamine-linked disorders with a higher incidence in males, such as schizophrenia or addiction,” said Dr Vilain.

One in seven people with Parkinson’s disease are diagnosed before the age of 50 years, and the prevalence increases with age. Parkinson’s disease worsens over time, and there is no known cause or cure. The severity and progression of the disease can vary greatly. Symptoms can be managed with medication and surgery.

http://www.phimr.monash.edu.au/

US researchers start that people with recollection problems who are depressed are at higher gamble of developing Alzheimer’s infection than people who
are not depressed, and that the lay Alzheimer’s medicine donepezil (brand name Aricept) may dally progress to Alzheimer’s in depressed people who
be dressed reminiscence problems or mild cognitive impairment (MCI).

The research was the being planned of take the lead architect Dr Po H Lu, aid professor of neurology with the David Geffen Way of life of Prescription at University of
California Los Angeles (UCLA), and colleagues, and is published online in the 16 June promulgation of Neurology, the medical scrapbook of the
American Academy of Neurology.

Lu said in a statement that:

“Our longer term findings add to the body of evidence that suggests impression is a major jeopardy factor recompense Alzheimer’s disease.”

“Since the drug donepezil has been shown to improve the behavioral symptoms of Alzheimer’s disease, our study also tested whether the analgesic would
delay the making to Alzheimer’s disease in people with memory problems,” he added.

A himself with Mild Cognitive Impairment (MCI) has problems with respect that are greater than those brought on by universal aging, but they don’t
show symptoms of Alzheimer’s such as distress completing every day activities.

For the study, Lu and colleagues followed the progress of 756 people between 55 and 91 years of age who had MCI and were taking part in a three-year, bent over-blind, placebo-controlled Alzheimer’s Disease Cooperative Study trial of donepezil and vitamin E.

A double blind thorn in the flesh is one where neither the participants nor the health professionals who make over them the drugs know whether they are taking the active drug or a placebo.

At the start of the den the participants underwent a examination that measured depression severity and intensity (the Beck Gloominess Inventory, BDI), and
208 were diagnosed with depression using the BDI.

The main outcome measure was train to possible or presumed Alzheimer’s disease, which was diagnosed either during or at the reason of the
trial.

The participants were in three goups: one troupe was given vitamin E, another donepezil and the third a placebo.

The results showed that:

• A participant’s risk of developing Alzheimer’s went up by 3 per cent for each point increase on the depression test.
• At 1.7 years into the study, among depressed-diagnosed participants with MCI, 11 per cent of those given donepezil developed Alzheimer’s disease
  compared to 25 per cent of those who were given vitamin E or placebo.
• At 2.2 years into the study, these figures went up to 14 per cent and 29 per cent respectively.
• Donepezil had little effect in the participants who were not diangosed with depression.

The authors concluded that:

“Results suggest that gloom is predictive of making from amnestic mild cognitive impairment (aMCI) to Alzheimer disease (AD) and
treatment with donepezil delayed progression to AD among depressed subjects with aMCI. Donepezil appears to balance the increased endanger of AD
conferred by the presence of depressive symptoms.”

Lu said:

“If we can delay the progress of this disease due to the fact that even two years, it could significantly look up the quality of life for many people dealing with
reminiscence disappointment.”

The FDA has not approved donepezil (Aricept) for the treatment of MCI but at best for mild to moderate and stern Alzheimer’s.

Alzheimer’s infection, which is named after the German physician Alois Alzheimer who first described it in 1906, is the most common formation of
dementia, accounting for 50 to 70 per cent of cases. It is a liberal and fatal brain disease with no cure and the 7th peerless creator of cessation in the
US.

Alzheimer’s destroys brain cells, causing problems with thought, thinking and behavior that impair faculty to work, relate to others, enjoy hobbies and
get on with every heyday life. The Nationwide Alliance on Aging reports that according to brand-new estimates, as many as 2.4 to 4.5 million Americans are
living with Alzheimer’s.

“Donepezil delays progression to AD in MCI subjects with depressive symptoms.”
Lu, P. H., Edland, S. D., Teng, E., Tingus, K., Petersen, R. C., Cummings, J. L., On behalf of The Alzheimer’s Disease Cooperative Study Group.
Neurology, 2009 72: 2115-2121.
Published online 16 June 2009.

Additional sources: American Academy of Neurology, Alzheimer’s Link, NIA.

Written by: Catharine Paddock, PhD

In consideration of drug information on ARICEPT.

Copyright: Medical News Today

Not to be reproduced without permission of Medical News Today